Company intelligence
AsymBio
Your Trusted Biologics CDMO
About AsymBio
Specializing in biologics, bioconjugates (ADCs, AOCs, PDCs, RDCs,APCs,DACs), antibodies and recombinant proteins, AsymBio, subsidiary of Asymchem Group, is a technology-driven global CDMO with operations in Tianjin and Shanghai. We deliver comprehensive end-to-end CDMO services, backed by a dedicated team of over 600 professionals, and provide seamless support spanning from early-stage R&D to commercial-scale manufacturing. Operating large-scale GMP-compliant biomanufacturing facilities, we adhere to an international quality management system fully aligned with rigorous regulatory requirements across the US, EU and China. As an innovative, reliable and client-centric partner, we are committed to driving your success in the highly competitive pharmaceutical landscape.
Verified activity
Signals from AsymBio
9 published signals
Presence & Recognition
AsymBio is attending the Antibody Innovation · TCEs at the Forefront conference in Shanghai on September 23, 2026.
Reported by AsymBio
Presence & Recognition
AsymBio is not directly mentioned in the LinkedIn post, but Harvard Griffin GSAS Biotech Club is announcing their annual career fair on Sept 30.
Reported by Josh Lang
Presence & Recognition
AsymBio is hosting a virtual networking event called BioXchange on Grapevine Network's interactive platform on Wednesday, September 30th.
Reported by Josh Lang
People
AsymBio is hiring a Marketing Specialist to join the team in Shanghai, China.
Reported by AsymBio
Strategy & Corporate Development
AsymBio is bringing together Asymchem’s oligonucleotide capabilities and AsymBio’s proprietary cell line development platform and conjugation toolbox to provide an integrated one-stop path from development and analytical characterization through manufacturing.
Reported by AsymBio
Presence & Recognition
AsymBio co-hosted China BioPioneers International Edition for Episode 2 on the ADC Commercialization Era on September 29, 2026.
Reported by AsymBio
Partnerships
AsymBio partner Treeline entered into a clinical trial collaboration and supply agreement with Roche to study TLN-121, Treeline’s BCL6 degrader, alongside Roche’s CD20xCD3 T-cell-engaging bispecific antibodies glofitamab and mosunetuzumab in patients with B-cell lymphomas.
Reported by Josh Lang
Presence & Recognition
AsymBio is hosting a live webinar on September 23 at 11:00 AM EDT and 8:00 AM PDT to discuss QbD- and risk-based thinking for biologics and ADC programs.
Reported by AsymBio
Presence & Recognition
AsymBio is hosting the Oncology & Immunology Innovation Partnering & Licensing Summit on September 9–10, 2026 at the Hotel Commonwealth in Boston, Massachusetts.
Reported by AsymBio